Deutsche Bank AG reaffirmed their buy rating on shares of Shire PLC (LON:SHP) in a report published on Friday. Deutsche Bank AG currently has a GBX 6,000 ($79.15) price target on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. Goldman Sachs Group, Inc. (The) restated a buy rating and issued a GBX 6,800 ($89.70) price objective on shares of Shire PLC in a research note on Wednesday, April 12th. Berenberg Bank restated a buy rating on shares of Shire PLC in a research note on Wednesday, April 12th. Citigroup Inc. restated a buy rating on shares of Shire PLC in a research note on Wednesday, April 12th. Shore Capital restated a buy rating on shares of Shire PLC in a research note on Monday, April 24th. Finally, Liberum Capital restated a buy rating and issued a GBX 5,500 ($72.55) price objective on shares of Shire PLC in a research note on Monday, April 10th. Three investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and a consensus target price of GBX 5,957.88 ($78.59).

COPYRIGHT VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/07/deutsche-bank-ag-reaffirms-buy-rating-for-shire-plc-lonshp.html.

In related news, insider Dominic Blakemore bought 152 shares of the stock in a transaction on Friday, June 30th. The shares were bought at an average cost of GBX 4,255 ($56.13) per share, for a total transaction of £6,467.60 ($8,531.33).

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.